Skip to main content
    C

    China Pharma Holdings Inc (CPHI)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • AMEX

    $0.52
    -0.04 (-7.47%)

    Market Cap: $22.29M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    China Pharma Holdings Inc (CPHI) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    China Pharma Holdings (CPHI) trades at 5.4x sales and 0.6x book value. Its forward P/E is 1.6x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E1.6x
    Price to sales5.4x
    Price to book0.6x
    PEGN/A
    As of Nov 17, 2026

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 0.2x in 2023 to 80.6x in 2019.

    Year endPriceP/SP/B
    2025$1.211.3x0.8x
    2024$2.330.5x0.6x
    2023$6.050.2x0.9x
    2022$47.95N/A71.9x
    2021$241.30N/AN/A
    2020$222.90N/AN/A
    2019$120.0080.6x191.2x
    2018$128.7025.9x19.7x
    2017$90.00N/A68.8x
    2016$130.00N/A84.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CPHI

    What is CPHI's forward P/E ratio?

    China Pharma Holdings has a forward P/E ratio of 1.6x.

    Is CPHI stock overvalued?

    GNG's valuation label for CPHI is Fairly valued.

    What is CPHI's price to sales ratio?

    China Pharma Holdings has a price to sales ratio of 5.4x.